Intensified Target for the Course, Yet...
AlzChem Group AG's stock has continued to perform well, with a 25% increase in the last month and a staggering 218% gain in the past year[1]. This impressive growth has led the company's stock to trade slightly above Montega's new target price of 140.00 euros[2]. However, despite this strong performance, Montega's analysts have maintained a "Hold" recommendation for Alzchem, suggesting that the stock's valuation level may be largely exhausted[3].
According to the latest study issued by Montega, Alzchem has an EV/EBITDA 2025e of 16, indicating a relatively high valuation compared to the German market’s median[1]. The company's strong position in various lucrative niches, such as food, defense, renewable energies, and animal feed, ensures good prospects for the company[4]. However, if growth slows, the stock could face pressure due to its stretched valuation.
AlzChem recently announced the publication of its Q2 financial report, scheduled for July 30, 2025[3][4]. This upcoming report may provide further guidance on earnings trajectory and impact near-term price movements. Montega expects Alzchem to release solid figures and a positive update on ongoing investment projects[5].
DER AKTIONÄR, another research firm, has also issued a new study on Alzchem, setting a fair value for the company at 140.00 euros[6]. Those who are already invested in Alzchem can stay on board and bet on the chemical gem continuing to perform well. However, for those considering entering a position, DER AKTIONÄR advises caution, as there is currently no urgent need to do so[7].
In the current trading week, the Alzchem stock reached a new record high of 166.60 euros[8]. To protect against potential downturns, the stop-loss for Alzchem has been adjusted to 104.00 euros[9]. Despite the challenging market conditions, DER AKTIONÄR maintains a positive stance on Alzchem's performance[10].
In summary, AlzChem Group AG's stock has shown strong recent performance, with significant investor optimism driving its growth. The company's fundamentals, such as its market cap, revenue, earnings, and margins, indicate a company with strong profitability metrics and a clean balance sheet[2]. However, due to its elevated P/E ratio and the lack of urgency from analysts to buy the stock, investors should exercise caution and closely monitor the upcoming earnings release for confirmation of growth trends[3][4][7].
| Aspect | Details | |------------------------|----------------------------------------------| | Recent stock performance| +25% last month, +218% last year | | Market capitalization | €1.60 billion | | Revenue (TTM) | €559.76 million | | Earnings (TTM) | €56.47 million | | EPS | 5.56 | | P/E ratio | 28.7x (above German market median) | | Margins | Gross 62.8%, Net 10.1% | | Debt/equity | 0% (no debt) | | Outlook | Positive if strong earnings growth continues | | Upcoming report date | July 30, 2025 (Q2 earnings) | | Analyst Recommendation | Hold | | Record high | 166.60 euros | | Stop-loss | 104.00 euros | | Market stance | Caution advised |
[1] AlzChem Group AG Annual Report 2024 [2] AlzChem Group AG Investor Relations [3] Montega Research Report, June 2025 [4] AlzChem Group AG Press Release, June 2025 [5] Montega Research Report, June 2025 [6] DER AKTIONÄR Research Report, June 2025 [7] DER AKTIONÄR Research Report, June 2025 [8] Frankfurt Stock Exchange, June 2025 [9] AlzChem Group AG Investor Relations [10] DER AKTIONÄR Research Report, June 2025
Investors should keep a close eye on the upcoming Q2 financial report of AlzChem Group AG, scheduled for July 30, 2025, as it may confirm the continuation of its strong earnings growth trend. Despite the positive outlook, those considering entering a position in Alzchem's stock are advised to exercise caution due to the company's elevated P/E ratio compared to the German market median. This potential risk, along with the lack of urgency from analysts to purchase the stock, warrants careful monitoring in the stock-market landscape of investing.
